Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1224P is a processed pseudogene derived from the U6 small nuclear RNA gene family. The canonical functional U6 snRNAs play a central role in the spliceosome, a large molecular complex responsible for the removal of introns from pre-mRNA during RNA splicing[3][1]. In contrast, RNU6-1224P, like other U6 snRNA pseudogenes, is considered non-functional, lacks the ability to form part of the spliceosomal machinery, and is typically not transcribed into a functional molecule[5]. Pseudogenes of snRNAs are thought to arise via retrotransposition events and can serve as markers for genome dynamics but are not implicated in therapeutic interventions or known biological pathways[5]. These pseudogenes do not encode proteins, do not interact with drugs, and have no documented safety or biomarker utility.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1224, pseudogene (RNU6-1224P).